Semiconductor Energy Laboratory Co., Ltd.

Takeda Pharmaceutical Company Limited

Ebara Corporation

Canon Kabushiki Kaisha

Millennium Pharmaceuticals Limited

Kabushiki Kaisha Toshiba

Mitsubishi Electric Corporation

Other

Ushio Denki Kabushiki Kaisha

Sumitomo Osaka Cement Co., Ltd.

Honda Tsushin Kogyo Co., Ltd.

Reborna Biosciences, Inc.

Koji Ono

Hideomi Suzawa

Shunpei Yamazaki

Tatsuya Arao

Yoshihiro Kusuyama

Jun Koyama

Toru Takayama

Yasuyuki Arai

Hirokazu Yamagata

Hiroshi Banno

Nobuki Sakauchi

Hideto Ohnuma

Kensuke Yoshizumi

Steven P Langston

Shinichi Imamura

He Xu

Hirotake Mizutani

Matthew O Duffey

Dylan Bradley England

Zhigen Hu

Charles McIntyre

Hisao Ikeda

Xin Liu

Takuto Kojima

Yoshiteru Ito

Keisuke Imamura

Yasuyoshi Arikawa

Takaharu Hirayama

Toshiro Maekawa

Noriyuki Nii

Brian Scott Freeze

Douglas Robert Cary

Youichi Kawakita

Satoshi Murakami

Yoshifumi Tanada

Mitsuru Mochizuki

Nobuharu Noji

Masahiro Ito

Toshio Tanaka

Atsushi Hirose

Masayuki Nakazawa

Kuniyuki Suzuki

Atsushi Shigeta

Etsuko Fujimoto

Hotaka Maruyama

Noriko Miyagi

Masako Kodera

Mutsumi Saito

Hidekazu Tokuhara

Hiroshi Sobukawa

Takayuki Nonami

Hironobu Maezaki

Yasuhiro Imaeda

Yasuhiro Hirata

Naohito Tomoe

Kenichi Shigeta

Yoshimi Adachi

Nobuo Cho

Masami Nagayama

Ryo Mizojiri

Moriteru Asano

Akinori Toita

Hironori Kokubo

Shozo Oguri

Jun Fujimoto

Fumiki Hasegawa

Kenichi Sasabe

Nao Morishita

Tadanori Egawa

Masami Jintyou

Tetsuji Togawa

Hiroki Adachi

Norio Kimura

Shingo Eguchi

Masataka Nakada

Takeshi Yamasaki

Manabu Tsujimura

Tamami Takahashi

Naoya Sakamoto

Masahiro Kajino

Atsushi Hasuoka

Shigemitsu Matsumoto

Kazuhiro Miwa

Haruyuki Nishida

Tadashi Matsushita

Tomohiko Sato

Masanori Okaniwa

Riichiro Aoki

Shiro Mishima

Yusuke Tominari

Atsushi Honda

Satomi Hamada

Gisuke Kouno

Naoki Iwamura

Mitsumasa Saito

Hiroki Takahagi

Taisuke Katoh

Hiroto Shinoda

Keizo Hirase

Kiyoshi Ooaku

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I):

Nitrogen containing heterocycles as CDK12 inhibitors

A prophylactic or therapeutic agent for spinal muscular atrophy according to the present invention includes a compound represented by the formula (I) or a salt thereof: the variables are described herein.

Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Heterocyclic compound

Provided is a compound represented by the following formula, or a salt thereof: 

Fused heterocyclic compound

A base station device is configured to set, for each communication terminal device, a radio format for signals transmitted to and received from the communication terminal device. The radio format is set for each communication terminal device in accordance with, for example, a type of use including a moving speed of the communication terminal device. The base station device may be configured to change the radio format for the communication terminal device based on the information about a change in the environment of a radio communication between the communication terminal device and the base station device and a change including the communication terminal device's location. The signals transmitted and received between the base station device and the communication terminal device include radio formats in which at least one of a length of a symbol of the signal and a length of a cyclic prefix in an OFDM scheme differs.

Communication system, base station, and communication terminal for controlling interference from neighboring cells

Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].

A metal wiring suitable for a substrate of large size is provided. The present invention is characterized in that at least one layer of conductive film is formed on an insulating surface, a resist pattern is formed on the conductive film, and the conductive film having the resist pattern is etched to form a metal wiring while controlling its taper angle &#x3b1; in accordance with the bias power density, the ICP power density, the temperature of lower electrode, the pressure, the total flow rate of etching gas, or the ratio of oxygen or chlorine in etching gas. The thus formed metal wiring has less fluctuation in width or length and can satisfactorily deal with an increase in size of substrate.

Metal wiring and method of manufacturing the same, and metal wiring substrate and method of manufacturing the same

Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, R, R', R, R, X, X, X, R, Z, and Zhave the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

Heteroaryl compounds useful as inhibitors of SUMO activating enzyme

A light source unit includes a light distribution lens configured to guide light emitted from an LED disposed behind the light distribution lens, and a reflector arranged to surround the light distribution lens. Illuminance unevenness can be more suitably reduced, and effective light is not blocked even if a pinhole device is used for glare prevention, thereby avoiding illuminance unevenness and illuminance reductions. The light distribution lens has a columnar part that extends in the optical axis direction, and a conical recess is formed in the distal end of the columnar part. The conical recess is constituted by a reflective surface that fully reflects, in the circumferential direction, light incident on the light distribution lens. The reflector reflects light emitted from a cylindrical side surface of the columnar part such that the reflected light becomes converging light.

Light source unit

Communication system

Heteroaryl compounds useful as inhibitors of sumo activating enzyme

Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, R, R, R, R, X, X, X, R, Z, and Zhave the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

The present invention provides a fused heterocyclic compound that has CDK 8 and/or CDK 19 inhibitory activity. The present invention provides a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof.

Growing community of inventors

Kanagawa, Japan

Koji Ono